Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).

NCT07365319 is registered in ClinicalTrials.gov with Eikon Therapeutics as lead sponsor.

NCT NCT07365319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07365319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).
Lead sponsor
Eikon Therapeutics
Phase
Phase 2/3
Overall status
Recruiting
Start date
June 15, 2026
Completion date
December 31, 2040
Enrollment
750 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer (squamous or non squamous), stage 4 nsclc